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to generate suﬃ  cient participants to meet power 
requirements for patient-centred outcomes.  
This trial is a timely reminder that although 
generalisability of treatment beneﬁ t can usually be 
assumed, the size of beneﬁ t cannot. True evidence-
based practice evolves from strategically planned 
research targeted at evidence gaps, and requires that 
clinicians are prepared to challenge their own cognitive 
biases to implement that evidence in their practice. 
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Plasma urate and coronary heart disease: ﬁ ngerprint match, 
but no smoking gun
In The Lancet Diabetes & Endocrinology, Jon White and 
colleagues1 consider the causal role of plasma urate in 
coronary heart disease, using the technique known as 
mendelian randomisation. They assess the association 
between genetic predictors of the risk factor (plasma 
urate) and the disease outcome (coronary heart disease), 
noting a statistically robust association between a genetic 
score based on 31 variants associated with plasma urate 
and coronary heart disease risk, with a straightforward 
application of Mendelian randomisation estimating an 
18% (95% CI 8-29) relative increase in coronary heart 
disease risk per 1 SD increase in plasma urate. This positive 
ﬁ nding from the mendelian randomisation investigation 
was in line with the observational epidemiological 
analysis also reported by the investigators. However, the 
association of the genetic score with the outcome seems 
to be at least partly explained by pleiotropic (oﬀ -target) 
associations of the genetic score, and the pattern of 
associations of the individual genetic variants does not 
show the characteristic dose–response association that 
would be expected if the genetic associations were solely 
driven by the eﬀ ect of the risk factor on the outcome.
Mendelian randomisation is a relatively new, but well 
established epidemiological technique to assess whether 
a modiﬁ able risk factor is a worthwhile target for clinical 
or pharmacological intervention.2,3 An association 
between a genetic predictor of the risk factor and the 
outcome is more likely to reﬂ ect that the risk factor 
has a causal relation with the outcome, compared with 
an association of the risk factor itself from a traditional 
epidemiological analysis, for several reasons. First, risk 
factors tend to be mutually correlated. It is diﬃ  cult to 
distinguish whether the risk factor itself is the cause, 
or if a correlated risk factor is driving the identiﬁ ed 
association with an outcome. By contrast, most genetic 
variants tend to be uncorrelated with conventional 
epidemiological risk factors.4 Second, genetic variants 
are ﬁ xed at conception. Hence, a genetic association 
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cannot be aﬀ ected by external factors that lead to 
confounded associations. Finally, the associations of 
genetic variants are not subject to reverse causation. The 
gene can only ever be the cause, and never the eﬀ ect. In 
an ideal mendelian randomisation analysis, the genetic 
variants have a clear biological link with the risk factor 
(for example, genetic variants in the CRP gene region for 
the analysis of C-reactive protein5), and are associated 
with the risk factor, but not with alternative risk factors. 
The analysis proceeds analogously to a randomised 
trial,6 and compares groups of individuals with (on 
average) genetically raised levels of the risk factor versus 
those with genetically lowered levels to assess whether 
the risk factor is a cause of the outcome, and therefore a 
promising target for prioritisation in drug development.
White and colleagues’ analysis1 is far from an ideal 
mendelian randomisation investigation. This is not a 
criticism, but a consequence of their investigation of a 
risk factor that is not a protein biomarker, and so does 
not have a coding gene region, as in the case of C-reactive 
protein. However, the consideration of multiple gene 
regions gives some robustness in the analysis, in that 
the consistency of any causal ﬁ nding can be assessed. If 
multiple independent genetic variants associated with 
the risk factor are all concordantly associated with the 
outcome (as in the case of LDL cholesterol with coronary 
heart disease7), the separate genetic associations each 
provide independent evidence for a causal eﬀ ect of the 
risk factor on the outcome, strengthening the evidence for 
a causal ﬁ nding. Another deﬁ ciency is that the composite 
genetic instrument considered by White and colleagues1 is 
not solely associated with urate concentrations, but also 
shows associations with other risk factors, including blood 
pressure and lipid fractions. This ﬁ nding is not necessarily 
a problem provided that the genetic associations with 
these factors are mediated by urate concentrations, and 
so one single causal pathway is represented. However, 
these associations might reﬂ ect pleiotropy of the genetic 
variants, meaning that there are multiple causal pathways 
from gene to disease, thereby violating the assumption of 
mendelian randomisation that an association between 
gene and disease reﬂ ects a causal eﬀ ect of the risk factor.
White and colleagues1 show a statistically robust 
association between their 31 variant composite 
instrument and disease risk. However, the authors 
are to be commended in not stopping here, as others 
have done previously, but instead seeking to assess 
whether potential violations of the instrumental variable 
assumptions invalidate a causal interpretation for their 
ﬁ ndings. They use two main statistical approaches: 
multivariable mendelian randomisation8 and Egger 
regression.9 In multivariable mendelian randomisation, 
alternative risk factors are accounted for by adjusting 
for the genetic associations with these risk factors in the 
analysis model. In Egger regression, the assessment is not 
simply of whether genetic variants that are associated 
with the risk factor are also associated with the outcome, 
but whether there is a dose–response relation in these 
associations—that is, are genetic variants that are 
more strongly associated with the risk factor also more 
strongly associated with the outcome? Egger regression 
also encompasses a test for directional pleiotropy—
whether this dose–response relation suggests that a 
variant having zero association with the risk factor also 
has zero association with the outcome (as expected if 
there is no pleiotropy, or balanced pleiotropy). Although 
multivariable mendelian randomisation does not suggest 
that measured pleiotropy completely accounts for the 
causal ﬁ nding, Egger regression detects pleiotropy 
among the genetic variants, and provides a weaker causal 
estimate (a 5% [95% CI -8 to 20] relative increase coronary 
heart disease risk per 1 SD increase in plasma urate) 
that is compatible with the null once this pleiotropy is 
accounted for. Additionally, the genetic associations with 
the outcome are more variable than would be expected by 
chance alone; this heterogeneity suggests that the genetic 
associations with coronary heart disease risk are not solely 
mediated via plasma urate concentrations.
The overall ﬁ nding is not unequivocal. There is an 
undeniable association between genetic predictors 
of plasma urate concentrations and risk of coronary 
heart disease. However, there are suggestions that the 
association might represent pleiotropic eﬀ ects of genetic 
variants included in the model, rather than a causal eﬀ ect 
of urate. In summary, the evidence presented honestly 
by White and colleagues1 suggests that urate lowering 
should be prioritised as a potential mechanism to improve 
cardiovascular outcomes, but without providing a smoking 
gun that puts the question of causality beyond doubt.
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In 2008, the US Food and Drug Administration 
(FDA) issued guidance for industry mandating 
that drug companies show that new drugs for the 
treatment of type 2 diabetes do not increase the risk 
of cardiovascular disease;1 however, this guidance 
focuses on cardiovascular death, myocardial infarction, 
and stroke, but not on heart failure.2 Type 2 diabetes 
is independently associated with an increased risk of 
admission to hospital with heart failure.3 Furthermore, 
heart failure caused by antidiabetic drugs has re-
emerged as a concern because of the increased risk of 
admission to hospital with heart failure associated with 
the DPP-4 inhibitor saxagliptin.4–6 Udell and colleagues7 
showed that glucose-lowering strategies might increase 
the risk of heart failure.7 The American College of 
Cardiology and American Heart Association8 deﬁ ne a 
heart failure event as worsening signs and symptoms of 
heart failure, signifying failure of the primary therapeutic 
management strategy, and resulting in escalation 
of therapy as an outpatient or requiring hospital 
admission.8 However, speciﬁ c deﬁ nitions of heart failure 
events used in clinical trials of antidiabetic drugs have 
not been systematically assessed. In view of recent 
clinical trial results, we propose an update to existing 
criteria for heart failure events. This Comment is based 
on discussions among scientists, clinical trialists, industry 
sponsors, and regulatory representatives, which took 
place at the 11th Global Cardiovascular Clinical Trialists 
Forum (Washington DC, USA; Dec 5–7, 2014).
We identiﬁ ed 15 completed antidiabetic drug trials 
(appendix). Five (33%) of these trials did not provide 
heart failure event deﬁ nitions. The UKPDS and ACCORD 
trials used non-speciﬁ c deﬁ nitions of heart failure 
events. More recent trials (EXAMINE, SAVOR-TIMI, 
TECOS, AleCardio, and EMPA-REG OUTCOME) provided 
more speciﬁ c heart failure criteria. Only the PROactive 
trial9,10 provided data for heart failure not requiring 
admission to hospital (appendix). None of the trials 
required a speciﬁ c biomarker (brain natriuretic peptide 
[BNP] or N-terminal pro-BNP [NT-pro-BNP]) cut-oﬀ  to 
deﬁ ne heart failure events. Heart failure deﬁ nitions in 
clinical trials have clearly been changing over time, with 
older trials using less precise deﬁ nitions and newer trials 
using more speciﬁ c deﬁ nitions—probably because of the 
increasing recognition of heart failure events in patients 
with type 2 diabetes.
Although the relative risks for heart failure within a 
trial are likely to be unbiased, the absolute estimates 
of heart failure risk will diﬀ er between trials because 
of diﬀ erences in heart failure event deﬁ nitions. This 
situation makes assessing heart failure results between 
diﬀ erent trials challenging. In the PROactive trial,9,10 heart 
failure events were reported as adverse events rather 
than as part of the primary composite endpoint, and 
were therefore not adjudicated. Although subsequent 
adjudication10 of events did not signiﬁ cantly change the 
results, because regional practices and the threshold for 
admitting patients with heart failure to hospital vary, 
masked adjudication with standardised deﬁ nitions 
of heart failure events is crucial to allow comparisons 
between studies. Worsening heart failure symptoms in 
patients who do not require admission to hospital are not 
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